- Home
- BCDA vs ILAG Comparison
BCDA vs ILAG Comparison
Compare BCDA & ILAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- ILAG
- Stock Information
- Founded
- BCDA N/A
- ILAG 1981
- Country
- BCDA United States
- ILAG Hong Kong
- Employees
- BCDA N/A
- ILAG N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- ILAG Office Equipment/Supplies/Services
- Sector
- BCDA Health Care
- ILAG Consumer Discretionary
- Exchange
- BCDA Nasdaq
- ILAG Nasdaq
- Market Cap
- BCDA 7.9M
- ILAG 18.4M
- IPO Year
- BCDA N/A
- ILAG 2022
- Fundamental
- Price
- BCDA $2.68
- ILAG $1.00
- Analyst Decision
- BCDA Strong Buy
- ILAG
- Analyst Count
- BCDA 1
- ILAG 0
- Target Price
- BCDA $25.00
- ILAG N/A
- AVG Volume (30 Days)
- BCDA 73.1K
- ILAG 46.6K
- Earning Date
- BCDA 11-06-2024
- ILAG 11-29-2024
- Dividend Yield
- BCDA N/A
- ILAG N/A
- EPS Growth
- BCDA N/A
- ILAG N/A
- EPS
- BCDA N/A
- ILAG N/A
- Revenue
- BCDA $428,000.00
- ILAG $6,443,357.00
- Revenue This Year
- BCDA $6.92
- ILAG N/A
- Revenue Next Year
- BCDA N/A
- ILAG N/A
- P/E Ratio
- BCDA N/A
- ILAG N/A
- Revenue Growth
- BCDA 0.71
- ILAG N/A
- 52 Week Low
- BCDA $1.96
- ILAG $0.33
- 52 Week High
- BCDA $23.25
- ILAG $1.35
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- ILAG 46.70
- Support Level
- BCDA $2.39
- ILAG $0.97
- Resistance Level
- BCDA $2.90
- ILAG $1.06
- Average True Range (ATR)
- BCDA 0.18
- ILAG 0.06
- MACD
- BCDA -0.00
- ILAG -0.01
- Stochastic Oscillator
- BCDA 53.70
- ILAG 24.24
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc is engaged in the business of manufacturing and selling mechanical locksets. The business is spread across the Unites States, Canada, Australia, and China. Majority of the revenue is generated from the United States.